Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03621644 · ClinicalTrials.gov registry record · NA
Stereotactic MRI-guided On-table Adaptive Radiation Therapy (SMART) for Locally Advanced Pancreatic Cancer
A NA study of Pancreatic Cancer, sponsored by Viewray.
- Active
- Registry status
- NA
- Development phase
- 133
- Enrollment target
- 13
- Study locations
NCT03621644: Active NA study of Pancreatic Cancer, sponsored by Viewray.
NCT03621644 is a NA study of Pancreatic Cancer that is active but no longer recruiting, run by Viewray. The registered enrollment target is 133 participants, below the 393-participant average among 278 other Pancreatic Cancer trials with a reported enrollment target (66% lower). The trial reports 13 study locations across 11 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03621644, a NA study of Pancreatic Cancer, is active but no longer recruiting, sponsored by Viewray.
- ACTIVE NOT RECRUITING
- Registry status
- NA
- Development phase
- 133 participants
- Enrollment target
- 13
- Study locations
Study Summary
High-dose magnetic resonance imaging (MRI) guided hypofractionated radiation therapy delivered using daily adaptive dose planning has been shown in a retrospective study to result in improved overall survival, relative to patients receiving lower radiation doses, in patients with locally advanced pancreatic cancer, without increasing the rate of serious gastrointestinal toxicity. The goal of the proposed trial is to investigative in a controlled, prospective manner the robustness of this outcome, and to track quality of life over a 5-year trial period.
Primary Outcome
Grade 3 or higher gastrointestinal toxicity assessed using Common Terminology Criteria for Adverse Events (CTCAE) v5 within 90 days of completion of radiation therapy
Conditions Studied
Interventions
- RADIATION Stereotactic MRI-guided On-table Adaptive Radiation Therapy
Study Locations (13)
Florida
- University of Miami - Miami
- Miami Cancer Institute - Miami
- Orlando Health - Orlando
California
- UCLA - Los Angeles
Massachusetts
- Dana-Farber Cancer Institute - Boston
Michigan
- Henry Ford Health Sciences - Detroit
Missouri
- Washington University - St Louis
New Hampshire
- Dartmouth-Hitchcock - Lebanon
New York
- Cornell University - New York
Oregon
- Providence Portland Cancer Center - Portland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 133 participants |
| Start Date | 2019-01-01 |
| Est. Completion | 2027-01 |
| Phase | NA |
What the registry record for NCT03621644 still lists
NCT03621644 is an interventional study that assigns participants to a tested intervention. The registered 133 participants enrollment target is mid-sized for trials with a published cap, below the 393-participant average among 278 other Pancreatic Cancer trials with a reported enrollment target (66% lower).
The record links to 1 condition, with Pancreatic Cancer appearing as the primary indexed condition, and to 1 intervention - of which Stereotactic MRI-guided On-table Adaptive Radiation Therapy is the first listed.
NCT03621644 lists 13 locations in 11 states (Florida, California, Massachusetts).
Frequently Asked Questions
What is clinical trial NCT03621644 about?
NCT03621644 is a clinical study titled "Stereotactic MRI-guided On-table Adaptive Radiation Therapy (SMART) for Locally Advanced Pancreatic Cancer". High-dose magnetic resonance imaging (MRI) guided hypofractionated radiation therapy delivered using daily adaptive dose planning has been shown in a retrospective study to result in improved overall survival, relative to patients receiving lower radiation doses, in patients with locally advanced pa...
What is the current status of trial NCT03621644?
This trial is currently active not recruiting. It is a NA study. The enrollment target is 133 participants. The study started on 2019-01-01. Estimated completion is 2027-01.
What conditions does trial NCT03621644 study?
This clinical trial studies the following conditions: Pancreatic Cancer.
What interventions are being tested in trial NCT03621644?
The interventions under investigation include: Stereotactic MRI-guided On-table Adaptive Radiation Therapy (RADIATION).
Who is sponsoring clinical trial NCT03621644?
This trial is sponsored by Viewray, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03621644 being conducted?
This trial has 13 study locations across California, Florida, Massachusetts, Michigan, Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pancreatic Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03621644's enrollment target sits among peer trials
133 87th of 278 higher than 192 of 278 other Pancreatic Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Pancreatic Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Alpha Radiation Emitters Device for the Treatment of Pancreatic Cancer With Chemotherapy for the Treatment of Locally Advanced and Metastatic Pancreatic Cancer
RECRUITING · NA
-
A Study of Radiation Therapy to Treat Solid Tumor Cancer That Has Spread to Soft Tissue
RECRUITING · NA
-
EUS Examination Using EndoSound Vision System vs. Standard Echoendoscope
RECRUITING · NA
-
Computed Tomography in Diagnosing Patients With Pancreatic or Hepatobiliary Cancer
RECRUITING · NA
-
Support Through Remote Observation and Nutrition Guidance Program (STRONG-PCS)
RECRUITING · NA
-
GENOCARE: A Prospective, Randomized Clinical Trial of Genotype-Guided Dosing Versus Usual Care
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04276870 · 133 participants · Phase 2
Orphan Indications for CD19 Redirected Autologous T Cells
- NCT04671771 · 133 participants · NA
A Study to Evaluate the Safety and Effectiveness of the InnAVasc Arteriovenous Graft for Hemodialysis Access in Patients With End-Stage Renal Disease
- NCT05610085 · 133 participants · Phase 2
A Dose Escalation Study of Levetiracetam in the Treatment of Neonatal Seizures
- NCT06206486 · 133 participants
The Gut Microbiome and Serum Metabolites As a Biological Mechanism Underlying Pain in Kidney Transplantation
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI